Table of Contents

2019-2024 Global Afatinib Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Afatinib Consumption 2014-2024
  • 2.1.2 Afatinib Consumption CAGR by Region
• 2.2 Afatinib Segment by Type
  • 2.2.1 30mg Tables
  • 2.2.2 40mg Tables
  • 2.2.3 50mg Tables
  • 2.2.4 25mg Tables
  • 2.2.5 20mg Tables
  • 2.2.6 Other
• 2.3 Afatinib Consumption by Type
  • 2.3.1 Global Afatinib Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Afatinib Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Afatinib Sale Price by Type (2014-2019)
• 2.4 Afatinib Segment by Application
  • 2.4.1 Hospital
  • 2.4.2 Clinic
  • 2.4.3 Drug Center
  • 2.4.4 Other
• 2.5 Afatinib Consumption by Application
  • 2.5.1 Global Afatinib Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Afatinib Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Afatinib Sale Price by Application (2014-2019)

3 Global Afatinib by Manufacturers

• 3.1 Global Afatinib Sales Market Share by Manufacturers
  • 3.1.1 Global Afatinib Sales by Manufacturers (2017-2019)
  • 3.1.2 Global Afatinib Sales Market Share by Manufacturers (2017-2019)
• 3.2 Global Afatinib Revenue Market Share by Manufacturers
  • 3.2.1 Global Afatinib Revenue by Manufacturers (2017-2019)
  • 3.2.2 Global Afatinib Revenue Market Share by Manufacturers (2017-2019)
• 3.3 Global Afatinib Sale Price by Manufacturers
• 3.4 Global Afatinib Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
  • 3.4.1 Global Afatinib Manufacturing Base Distribution and Sales Area by Manufacturers
  • 3.4.2 Players Afatinib Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Afatinib by Regions

• 4.1 Afatinib by Regions
  • 4.1.1 Global Afatinib Consumption by Regions
  • 4.1.2 Global Afatinib Value by Regions
• 4.2 Americas Afatinib Consumption Growth
• 4.3 APAC Afatinib Consumption Growth
• 4.4 Europe Afatinib Consumption Growth
• 4.5 Middle East & Africa Afatinib Consumption Growth

5 Americas

• 5.1 Americas Afatinib Consumption by Countries
  • 5.1.1 Americas Afatinib Consumption by Countries (2014-2019)
  • 5.1.2 Americas Afatinib Value by Countries (2014-2019)
• 5.2 Americas Afatinib Consumption by Type
• 5.3 Americas Afatinib Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Afatinib Consumption by Countries
  • 6.1.1 APAC Afatinib Consumption by Countries (2014-2019)
  • 6.1.2 APAC Afatinib Value by Countries (2014-2019)
• 6.2 APAC Afatinib Consumption by Type
• 6.3 APAC Afatinib Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Afatinib by Countries
  • 7.1.1 Europe Afatinib Consumption by Countries (2014-2019)
  • 7.1.2 Europe Afatinib Value by Countries (2014-2019)
• 7.2 Europe Afatinib Consumption by Type
• 7.3 Europe Afatinib Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Afatinib by Countries
  • 8.1.1 Middle East & Africa Afatinib Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Afatinib Value by Countries (2014-2019)
• 8.2 Middle East & Africa Afatinib Consumption by Type
• 8.3 Middle East & Africa Afatinib Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Afatinib Distributors
• 10.3 Afatinib Customer

11 Global Afatinib Market Forecast

• 11.1 Global Afatinib Consumption Forecast (2019-2024)
• 11.2 Global Afatinib Forecast by Regions
  • 11.2.1 Global Afatinib Forecast by Regions (2019-2024)
  • 11.2.2 Global Afatinib Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Afatinib Forecast by Type
• 11.8 Global Afatinib Forecast by Application

12 Key Players Analysis

• 12.1 Boehringer Ingelheim
  • 12.1.1 Company Details
  • 12.1.2 Afatinib Product Offered
  • 12.1.3 Boehringer Ingelheim Afatinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Boehringer Ingelheim News
• 12.2 Hengrui Medicine
  • 12.2.1 Company Details
  • 12.2.2 Afatinib Product Offered
  • 12.2.3 Hengrui Medicine Afatinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Hengrui Medicine News
• 12.3 Beacon Pharma
  • 12.3.1 Company Details
  • 12.3.2 Afatinib Product Offered
  • 12.3.3 Beacon Pharma Afatinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Beacon Pharma News

...

13 Research Findings and Conclusion

According to this study, over the next five years the Afatinib market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Afatinib business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Afatinib market by product type, application, key manufacturers and key regions and countries.

This study considers the Afatinib value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
30mg Tables
40mg Tables
50mg Tables
25mg Tables
20mg Tables
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Clinic
Drug Center
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Boehringer Ingelheim
Hengrui Medicine
Beacon Pharma
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Afatinib consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Afatinib market by identifying its various subsegments.
Focuses on the key global Afatinib manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Afatinib with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Afatinib submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.